OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

About this update from Onemednet Corp

[{"type":"image","alt":"OneMedNet Corporation","displaySize":"","headline":null,"caption":"OneMedNet Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":288,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/513a33742df6a2a84791e6f654a8cce2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2hbxIN4EykXt6moj0t_15Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/513a33742df6a2a84791e6f654a8cce2","width":288,"height":117}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations.","length":285,"tagName":"p"},{"type":"text","content":"This partnership expands OneMedNet’s autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet’s portfolio of high-value specialty datasets and supporting research, AI model development, HEOR initiatives, and regulatory-aligned use cases.","length":490,"tagName":"p"},{"type":"text","content":"Autoimmune Real-World Data is highly sought after by pharmaceutical and biotechnology companies developing innovative therapies for these chronic conditions. The addition of ViuHealth’s longitudinal dataset—capturing patient journeys, treatment adherence, flares, and outcomes—enables pharma partners to accelerate drug discovery, support label expansions, demonstrate real-world effectiveness in competitive markets, and inform pricing or reimbursement strategies in a therapeutics segment projected to exceed $166 billion globally in 20261.","length":542,"tagName":"p"},{"type":"text","content":"Driving Recurring Revenue Growth","length":32,"tagName":"p"},{"type":"text","content":"This partnership advances OneMedNet’s subscription revenue strategy by integrating high-value, disease-specific longitudinal data into the iRWD™ platform.","length":154,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Subscription License: ...

More updates from Onemednet Corp